Delcath Systems sees Q4 revenue $15.1M, consensus $12.42M

Total fourth quarter and full year revenue expected to be approximately $15.1 M and $37.2M , respectively HEPZATO KIT fourth quarter and full year revenue expected to be approximately $13.7M and $32.3M , respectively CHEMOSATfourth quarter and full year revenue expected to be approximately $1.4 million and $4.9 million, respectively Gross margins expected to be in the 80%-85% range; As of December 31, 2024, the Company had approximately $53.2 million of cash, cash equivalents and short-term investments and no debt Final financial results for the fourth quarter and full year 2024 and a detailed business update will be provided during Delcath’s annual financial results release and investor call scheduled for March 6, 2025.